Human genetic variants and age are the strongest predictors of humoral immune responses to common pathogens and vaccines by Intérieur Consortium, Milieu et al.
HAL Id: pasteur-01758699
https://hal-pasteur.archives-ouvertes.fr/pasteur-01758699
Submitted on 4 Apr 2018
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Distributed under a Creative Commons Attribution| 4.0 International License
Human genetic variants and age are the strongest
predictors of humoral immune responses to common
pathogens and vaccines
Milieu Intérieur Consortium, Petar Scepanovic, Cécile Alanio, Christian
Hammer, Flavia Hodel, Jacob Bergstedt, Etienne Patin, Christian Thorball,
Nimisha Chaturvedi, Bruno Charbit, et al.
To cite this version:
Milieu Intérieur Consortium, Petar Scepanovic, Cécile Alanio, Christian Hammer, Flavia Hodel, et al..
Human genetic variants and age are the strongest predictors of humoral immune responses to common
pathogens and vaccines. Genome Medicine, BioMed Central, 2018, 10 (1), pp.59. ￿10.1186/s13073-
018-0568-8￿. ￿pasteur-01758699￿
1  
Genetic factors and age are the strongest predictors of humoral 
immune responses to common pathogens and vaccines 
 
Petar Scepanovic1,2†, Cécile Alanio3,4,5†, Christian Hammer1,2,6, Flavia Hodel1,2, Jacob 
Bergstedt7, Etienne Patin8,9,10, Christian W. Thorball1,2, Nimisha Chaturvedi1,2, Bruno 
Charbit4, Laurent Abel11,12,13, Lluis Quintana-Murci8,9,10, Darragh Duffy3,4,5, Matthew L. 
Albert6*, Jacques Fellay1,2,14* for The Milieu Intérieur Consortium 
 
† These authors contributed equally to the study 
* Corresponding Authors  
 
 
1 School of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland 
2 Swiss Institute of Bioinformatics, Lausanne, Switzerland 
3 Immunobiology of Dendritic Cell Unit, Institut Pasteur, Paris, France 
4 Center for Translational Research, Institut Pasteur, Paris, France 
5 Inserm U1223, Institut Pasteur, Paris, France 
6 Department of Cancer Immunology, Genentech, South San Francisco, CA, USA 
7 Department of Automatic Control, Lund University, Lund, Sweden 
8 Unit of Human Evolutionary Genetics, Department of Genomes and Genetics, Institut 
Pasteur, Paris, France 
9 Centre National de la Recherche Scientifique, URA 3012, Paris, France 
10 Center of Bioinformatics, Biostatistics and Integrative Biology, Institut Pasteur, Paris 
75015, France 
11 Laboratory of Human Genetics of Infectious Diseases, Necker branch, Inserm U1163, 
Paris, France 
12 Paris Descartes University, Imagine Institute, Paris, France 
13 St Giles laboratory of Human Genetics of Infectious Diseases, Rockefeller branch, The 
Rockefeller University, New York, NY, USA 
14 Precision Medicine Unit, Lausanne University Hospital, Lausanne, Switzerland 
 
 
The Milieu Intérieur Consortium is composed of the following team leaders: Laurent Abel (Hôpital 
Necker), Andres Alcover, Hugues Aschard, Kalla Astrom (Lund University), Philippe Bousso, Pierre 
Bruhns, Ana Cumano, Caroline Demangel, Ludovic Deriano, James Di Santo, Françoise Dromer, 
Darragh Duffy, Gérard Eberl, Jost Enninga, Jacques Fellay (EPFL, Lausanne), Magnus Fontes, Antonio 
Freitas, Odile Gelpi, Ivo Gomperts-Boneca, Serge Hercberg (Université Paris 13), Olivier Lantz 
(Institut Curie), Claude Leclerc, Hugo Mouquet, Etienne Patin, Sandra Pellegrini, Stanislas Pol (Hôpital 
Cochin), Antonio Raussel (INSERM UMR 1163 – Institut Imagine), Lars Rogge, Anavaj Sakuntabhai, 
Olivier Schwartz, Benno Schwikowski, Spencer Shorte, Vassili Soumelis (Institut Curie), Frédéric 
Tangy, Eric Tartour (Hôpital Européen George Pompidou), Antoine Toubert (Hôpital Saint-Louis), 
Marie-Noëlle Ungeheuer, Lluis Quintana-Murci§, Matthew L. Albert§  
Additional information can be found at: http://www.pasteur.fr/labex/milieu-interieur  
§ Co-coordinators of the Milieu Intérieur Consortium  
 
  
.CC-BY-NC-ND 4.0 International licensenot peer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was. http://dx.doi.org/10.1101/254706doi: bioRxiv preprint first posted online Jan. 27, 2018; 
2  
Abstract 
 
Introduction. Humoral immune responses to infectious agents or vaccination vary 
substantially among individuals, and many of the factors responsible for this variability 
remain to be defined. Current evidence suggests that human genetic variation influences  
(i) serum immunoglobulin levels, (ii) seroconversion rates, and (iii) intensity of antigen-
specific immune responses. Here, we evaluate the impact of intrinsic (age and sex), 
environmental and genetic factors on the variability of humoral response to common 
pathogens and vaccines. 
 
Methods. We characterized the serological response to 15 antigens from common human 
pathogens or vaccines, in an age- and sex-stratified cohort of 1,000 healthy individuals 
(Milieu Intérieur cohort). Using clinical-grade serological assays, we measured total IgA, IgE, 
IgG and IgM levels, as well as qualitative (serostatus) and quantitative IgG responses to 
cytomegalovirus, Epstein-Barr virus, herpes simplex virus 1 & 2, varicella zoster virus, 
Helicobacter pylori, Toxoplasma gondii, influenza A virus, measles, mumps, rubella, and 
hepatitis B virus. Following genome-wide genotyping of single nucleotide polymorphisms 
and imputation, we examined associations between ~5 million genetic variants and 
antibody responses using single marker and gene burden tests. 
 
Results and discussion. We identified age and sex as important determinants of humoral 
response, with older individuals and women having higher rates of seropositivity for most 
antigens. Genome-wide association studies revealed significant associations between 
variants in the human leucocyte antigen (HLA) class II region on chromosome 6 and anti-EBV 
and anti-rubella IgG levels. We used HLA imputation to fine map these associations to amino 
acid variants in the peptide-binding groove of HLA-DRβ1 and HLA-DPβ1, respectively. We 
also observed significant associations for total IgA levels with two loci on chromosome 2 and 
with specific KIR-HLA combinations.  
 
Conclusions. Using extensive serological testing and genome-wide association analyses in a 
well-characterized cohort of healthy individuals, we demonstrate that age, sex and specific 
human genetic variants contribute to inter-individual variability in humoral response. By 
highlighting genes and pathways implicated in the normal antibody response to frequently 
encountered antigens, these findings provide a basis to better understand disease 
pathogenesis. 
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Introduction 
 
Humans are regularly exposed to infectious agents, including common viruses such as 
cytomegalovirus (CMV), Epstein-Barr virus (EBV) or herpes simplex virus-1 (HSV-1), that 
have the ability to persist as latent infections throughout life – with possible reactivation 
events depending on extrinsic and intrinsic factors [1]. Humans also receive multiple 
vaccinations, which in many cases are expected to achieve lifelong immunity in the form of 
neutralizing antibodies. In response to each of these stimulations, the immune system 
mounts a humoral response, triggering the production of specific antibodies that play an 
essential role in limiting infection and providing long-term protection. Although the intensity 
of the humoral response to a given stimulation has been shown to be highly variable [2, 3, 
4], the genetic and non-genetic determinants of this variability are still largely unknown. The 
identification of such factors may lead to improved vaccination strategies by optimizing 
vaccine-induced immunoglobulin G (IgG) protection, or to new understanding of 
autoimmune diseases, where immunoglobulin levels can correlate with disease severity [5].  
 
Several genetic variants have been identified that account for inter-individual differences in 
susceptibility to pathogens [6, 7, 8], and in infectious [9] or therapeutic [10] phenotypes. By 
contrast, relatively few studies have investigated the variability of humoral responses in 
healthy humans [4, 11, 12]. In particular, Hammer C., et al. examined the contribution of 
genetics to variability in human antibody responses to common viral antigens, and fine-
mapped variants at the HLA class II locus that associated with IgG responses. To replicate 
and extend these findings, we measured IgG responses to 15 antigens from common 
infectious agents or vaccines as well as total IgG, IgM, IgE and IgA levels in 1,000 well-
characterized healthy donors. We used an integrative approach to study the impact of age, 
sex, non-genetic and genetic factors on humoral responses in healthy humans.  
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Methods 
 
Study participants 
The Milieu Intérieur cohort consists of 1,000 healthy individuals that were recruited by 
BioTrial (Rennes, France). The cohort is stratified by sex (500 men, 500 women) and age 
(200 individuals from each decade of life, between 20 and 70 years of age). Donors were 
selected based on stringent inclusion and exclusion criteria, previously described [13]. 
Briefly, recruited individuals had no evidence of any severe/chronic/recurrent medical 
conditions. The main exclusion criteria were: seropositivity for human immunodeficiency 
virus (HIV) or hepatitis C virus (HCV); ongoing infection with the hepatitis B virus (HBV) – as 
evidenced by detectable HBs antigen levels; travel to (sub-)tropical countries within the 
previous 6 months; recent vaccine administration; and alcohol abuse. To avoid the influence 
of hormonal fluctuations in women during the peri-menopausal phase, only pre- or post-
menopausal women were included. To minimize the importance of population substructure 
on genomic analyses, the study was restricted to self-reported Metropolitan French origin 
for three generations (i.e., with parents and grandparents born in continental France). 
Whole blood samples were collected from the 1,000 fasting healthy donors on lithium 
heparin tubes, from September 2012 to August 2013. The clinical study was approved by the 
Comité de Protection des Personnes - Ouest 6 on June 13th, 2012, and by the French 
Agence Nationale de Sécurité du Médicament (ANSM) on June 22nd, 2012. The study is 
sponsored by Institut Pasteur (Pasteur ID-RCB Number: 2012-A00238-35), and was 
conducted as a single center study without any investigational product. The protocol is 
registered under ClinicalTrials.gov (study# NCT01699893). 
 
Serologies 
Total IgG, IgM, IgE, and IgA levels were measured using clinical grade turbidimetric test on 
AU 400 Olympus at the BioTrial (Rennes, France). Antigen-specific serological tests were 
performed using clinical-grade assays measuring IgG levels, according to the manufacturer's 
instructions. A list and description of the assays is provided in Table S1. Briefly, anti-HBs and 
anti-HBc IgGs were measured on the Architect automate (CMIA assay, Abbott). Anti-CMV 
IgGs were measured by CMIA using the CMV IgG kit from Beckman Coulter on the Unicel Dxl 
800 Access automate (Beckman Coulter). Anti-Measles, anti-Mumps and anti-Rubella IgGs 
were measured using the BioPlex 2200 MMRV IgG kit on the BioPlex 2200 analyzer (Bio-
Rad). Anti-Toxoplasma gondi, and anti-CMV IgGs were measured using the BioPlex 2200 
ToRC IgG kit on the BioPlex 2200 analyzer (Bio-Rad). Anti-HSV1 and anti-HSV2 IgGs were 
measured using the BioPlex 2200 HSV-1 & HSV-2 IgG kit on the BioPlex 2200 analyzer (Bio-
Rad). IgGs against Helicobacter Pylori were measured by EIA using the PLATELIA H. Pylori IgG 
kit (BioRad) on the VIDAS automate (Biomérieux). Anti-influenza A IgGs were measured by 
ELISA using the NovaLisa IgG kit from NovaTec (Biomérieux). In all cases, the criteria for 
serostatus definition (positive, negative or indeterminate) were established by the 
manufacturer, and are indicated in Table S2. Donors with an unclear result were retested, 
and assigned a negative result if borderline levels were confirmed with repeat testing. 
 
Non-genetic variables 
A large number of demographical and clinical variables are available in the Milieu Intérieur 
cohort as a description of the environment of the healthy donors [13]. These include 
infection and vaccination history, childhood diseases, health-related habits, and socio-
demographical variables. Of these, 53 where chosen for subsequent analysis of their impact 
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on serostatus. This selection is based on the one done in [14], with a few variables added, 
such as measures of lipids and CRP. 
 
Testing of non-genetic variables 
Using serostatus variables as the response, and non-genetic variables as treatment 
variables, we fitted a logistic regression model for each response and treatment variable 
pair.   A total of 14 * 52 = 742 models where therefore fitted. Age and sex where included as 
controls for all models, except if that variable was the treatment variable. We tested the 
impact of the clinical and demographical variables using a likelihood ratio test. All 742 tests 
where considered a multiple testing family with the false discovery rate (FDR) as error rate. 
 
Age and sex testing 
To examine the impact of age and sex we performed logistic and linear regression analyses 
for serostatus and IgG levels, respectively. All continuous traits (i.e. quantitative 
measurements of antibody levels) were log10-transformed in donors assigned as positive 
using a clinical cutoff. We used false discovery rate (FDR) correction for the number of 
serologies tested (associations with P < 0.05 were considered significant). To calculate odd 
ratios in the age analyses, we separated the cohort in equal numbers of young (<45 years 
old) and old (>=45 years old) individuals, and utilized the epitools R package (v0.5-10). 
 
DNA genotyping 
Blood was collected in 5mL sodium EDTA tubes and was kept at room temperature (18–25°) 
until processing. DNA was extracted from human whole blood and genotyped at 719,665 
single nucleotide polymorphisms (SNPs) using the HumanOmniExpress-24 BeadChip 
(Illumina). The SNP call rate was higher than 97% in all donors. To increase coverage of rare 
and potentially functional variation, 966 of the 1,000 donors were also genotyped at 
245,766 exonic variants using the HumanExome-12 BeadChip. The HumanExome variant call 
rate was lower than 97% in 11 donors, which were thus removed from this dataset. We 
filtered out from both datasets genetic variants that: (i) were unmapped on dbSNP138, (ii) 
were duplicated, (iii) had a low genotype clustering quality (GenTrain score < 0.35), (iv) had 
a call rate < 99%, (v) were monomorphic, (vi) were on sex chromosomes, or (vii) diverged 
significantly from Hardy-Weinberg equilibrium (HWE P < 10-7). These quality-control filters 
yielded a total of 661,332 and 87,960 variants for the HumanOmniExpress and 
HumanExome BeadChips, respectively. Average concordance rate for the 16,753 SNPs 
shared between the two genotyping platforms was 99.9925%, and individual concordance 
rates ranged from 99.8% to 100%.  
 
Genetic relatedness and structure  
As detailed elsewhere [14], relatedness was detected using KING [15]. Six pairs of related 
participants (parent-child, first and second degree siblings) were detected and one 
individual from each pair, randomly selected, was removed from the genetic analyses. The 
genetic structure of the study population was estimated using principal component analysis 
(PCA), implemented in EIGENSTRAT (v6.1.3) [16]. 
 
Genotype imputation 
We used Positional Burrows-Wheeler Transform for genotype imputation, starting with the 
661,332 quality-controlled SNPs genotyped on the HumanOmniExpress array. Phasing was 
performed using EAGLE2 (v2.0.5) [17]. As reference panel, we used the haplotypes from the 
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Haplotype Reference Consortium (release 1.1) [18]. After removing SNPs that had an 
imputation info score < 0.8 we obtained 22,235,661 variants. We then merged the imputed 
dataset with 87,960 variants directly genotyped on the HumanExome BeadChips array and 
removed variants that were monomorphic or diverged significantly from Hardy-Weinberg 
equilibrium (P < 10-7). We obtained a total of 12,058,650 genetic variants to be used in 
association analyses. 
We used SNP2HLA (v1.03) [19] to impute 104 4-digit HLA alleles and 738 amino acid 
residues (at 315 variable amino acid positions of the HLA class I and II proteins) with a minor 
allele frequency (MAF) of >1%.  
We used KIR*IMP [20] to impute KIR alleles, after haplotype inference on chromosome 19 
with SHAPEIT2 (v2.r790) [21]. A total of 19 KIR types were imputed: 17 loci plus two 
extended haplotype classifications (A vs. B and KIR haplotype). A MAF threshold of 1% was 
applied, leaving 16 KIR alleles for association analysis.  
 
Genetic association analyses 
For single variant association analyses, we only considered SNPs with a MAF of >5% 
(N=5,699,237). We used PLINK (v1.9) [22] to perform logistic regression for binary 
phenotypes (serostatus: antibody positive versus negative) and linear regression for 
continuous traits (log10-transformed quantitative measurements of antibody levels in 
donors assigned as positive using a clinical cutoff). The first two principal components of a 
PCA based on genetic data, age and sex were used as covariates in all tests. In order to 
correct for baseline difference in IgG production in individuals, total IgG levels were included 
as covariates when examining associations with antigen-specific antibody levels, total IgM, 
IgE and IgA levels. From a total of 53 additional variables additional co-variates, selected by 
using elastic net [23] and stability selection [24] as detailed elsewhere [14], were included in 
some analyses (Table S3). For all antigen-specific genome-wide association studies, we used 
a genome-wide significant threshold (Pthreshold < 3.3 x 10-9) corrected for the number of 
antigens tested (N=15). For genome-wide association tests with total Ig levels we set the 
threshold at Pthreshold < 1.3 x 10-8, correcting for the four immunoglobulin classes tested. For 
specific HLA analyses, we used PLINK (v1.07) [25] to perform conditional haplotype-based 
association tests and multivariate omnibus tests at multi-allelic amino acid positions. 
 
Variant annotation and gene burden testing 
We used SnpEff (v4.3g) [26] to annotate all 12,058,650 variants. A total of 84,748 variants 
were annotated as having (potentially) moderate (e.g. missense variant, inframe deletion, 
etc.) or high impact (e.g. stop gained, frameshift variant, etc.) and were included in the 
analysis.  We used bedtools v2.26.0 [27] to intersect variant genomic location with gene 
boundaries, thus obtaining sets of variants per gene. By performing kernel-regression-based 
association tests with SKAT_CommonRare (testing the combined effect of common and rare 
variants) and SKATBinary implemented in the SKAT v1.2.1 [28], we tested 16,628 gene sets 
for association with continuous and binary phenotypes, respectively. By SKAT default 
parameters, variants with MAF ≤ !√#$ are considered rare, whereas variants with MAF ≥ !√#$ 
were considered common, where N is the sample size. We used Bonferroni correction for 
multiple testing, accounting for the number of gene sets and phenotypes tested (Pthreshold < 2 
x 10-7 for antigen-specific tests and Pthreshold < 7.5 x 10-7 for tests with total Ig levels). 
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Results 
 
Characterization of humoral immune responses in the 1,000 study participants 
To characterize the variability in humoral immune responses between healthy individuals, 
we measured total IgG, IgM, IgA and IgE levels in the plasma of the 1,000 donors of the 
Milieu Interieur (MI) cohort. After log10 transformation, total IgG, IgM, IgA and IgE levels 
showed normal distributions, with a median ± sd of 1.02 ±0.08 g/l, 0.01 ±0.2 g/l, 0.31 ±0.18 
g/l and 1.51 ±0.62 UI/ml, respectively (Figure S1A).  
 
We then evaluated specific IgG responses to multiple antigens from the following infections 
and vaccines: (i) 7 common persistent pathogens, including five viruses: CMV, EBV (EA, 
EBNA, and VCA antigens), herpes simplex virus 1 & 2 (HSV-1 & 2), varicella zoster virus 
(VZV), one bacterium: Helicobacter pylori (H. Pylori), and one parasite: Toxoplasma gondii 
(T. Gondii); (ii) one recurrent virus: influenza A virus (IAV); and (iii) four viruses for which 
most donors received vaccination: measles, mumps, rubella, and HBV (HBs and HBc 
antigens) (Figure 1). The distributions of log10-transformed antigen-specific IgG levels in the 
1,000 donors for the 15 serologies are shown in Figure S1B. Donors were classified as 
seropositive or seronegative using the thresholds recommended by the manufacturer (Table 
S2).  
 
The vast majority of the 1,000 healthy donors were chronically infected with EBV 
(seropositivity rates of 96% for EBV VCA, 91% for EBV EBNA and 9% for EBV EA) and VZV 
(93%). Many also showed high-titer antibodies specific for IAV (77%), HSV-1 (65%), and T. 
Gondii (56%). By contrast, fewer individuals were seropositive for CMV (35%), HSV-2 (21%), 
and H. Pylori (18%) (Figure 1, Figure S2A and Table S2). The majority of healthy donors 
carried antibodies against 5 or more persistent/recurrent infections of the 8 infectious 
agents tested (Figure S2B). 51% of MI donors were positive for anti-HBs IgG - a large 
majority of them as a result of vaccination, as only 15 study participants (3% of the anti-HBs 
positive group) were positive for anti-HBc IgG, indicative of previous HBV infection 
(spontaneously cured, as all donors were negative for HbS antigen, criteria for inclusion in 
the study). For rubella, measles, and mumps, seropositivity rates were 94%, 91%, and 89% 
respectively. For the majority of the donors, this likely reflects vaccination with a trivalent 
vaccine, which was integrated in 1984 as part of national recommendations in France, but 
for some – in particular the >40 year-old individuals of the cohort, it may reflect acquired 
immunity due to natural infection.  
 
Associations of age, sex, and non-genetic variables with serostatus  
Subjects included in the Milieu Interieur cohort were surveyed for a large number of 
variables related to infection and vaccination history, childhood diseases, health-related 
habits, and socio-demographical variables (http://www.milieuinterieur.fr/en/research-
activities/cohort/crf-data). Of these, 53 where chosen for subsequent analysis of their 
impact on serostatus. This selection is based on the one done in [14], with a few variables 
added, such as measures of lipids and CRP. Applying a mixed model analysis that controls 
for potential confounders and batch effects, we found expected associations of HBs 
seropositivity with previous administration of HBV vaccine, as well as of Influenza 
seropositivity with previous administration of Flu vaccine (Figure S3A and Table S4). We also 
found associations of HBs seropositivity with previous administration of Typhoid and 
Hepatitis A vaccines - which likely reflects co-immunization, as well as with Income, 
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Employment, and Owning a house – which likely reflects confounding epidemiological 
factors.  
 
We observed a significant impact of age on the probability of being seropositive for antigens 
from persistent or recurrent infectious agents and/or vaccines. For 14 out of the 15 
examined serologies, older people (> 45 years old) were more likely to have detectable 
specific IgG, with an odds ratio (OR; mean ± SD) of 5.4 ± 8.5 (Figure 2A, Figure S3B and Table 
S5). We identified four different profiles of age-dependent evolution of seropositivity rates 
(Figure 2B and Figure S4). Profile 1 is typical of childhood-acquired infection, i.e. microbes 
that most donors had encountered by age 20 (EBV, VZV, and influenza). We observed in this 
case either (i) a limited increase in seropositivity rate after age 20 for EBV; (ii) stability for 
VZV; or (iii) a small decrease in seropositivity rate with age for IAV (Figure S4A-E). Profile 2 
concerns prevalent infectious agents that are acquired throughout life, with steadily 
increasing prevalence (observed for CMV, HSV-1, and T. gondii). We observed in this case 
either (i) a linear increase in seropositivity rates over the 5 decades of age for CMV 
(seropositivity rate: 24% in 20-29 years-old; 44% in 60-69 years-old; slope=0.02) and T. 
Gondii (seropositivity rate: 21% in 20-29 years-old; 88% in 60-69; slope=0.08); or (ii) a non-
linear increase in seropositivity rates for HSV-1, with a steeper slope before age 40 
(seropositivity rate: 36% in 20-29 years-old; 85% in 60-69; slope=0.05) (Figure S4F-H). Profile 
3 showed microbial agents with limited seroprevalence - in our cohort, HSV-2, HBV (anti-
HBS and anti-HBc positive individuals, indicating prior infection rather than vaccination), and 
H. Pylori. We observed a modest increase of seropositivity rates throughout life, likely 
reflecting continuous low-grade exposure (Figure S4I-K). Profile 4 is negatively correlated 
with increasing age and is unique to HBV anti-HBs serology (Figure S4L). This reflects the 
introduction of the HBV vaccine in 1982 and the higher vaccination coverage of younger 
populations. Profiles for Measles, Mumps and Rubella are provided in Figure S4M-O.  
 
We also observed a significant association between sex and serostatus for 7 of the 15 
antigens, with a mean OR of 1.5 ± 0.5 (Figure 2C, Figure S3C and Table S5). For six serological 
phenotypes, women had a higher rate of positivity, IAV being the notable exception. These 
associations were confirmed when considering “Sharing house with partner”, and “Sharing 
house with children” as covariates. 
 
Impact of age and sex on total and antigen-specific antibody levels 
We further examined the impact of age and sex on the levels of total IgG, IgM, IgA and IgE 
detected in the serum of the patients, as well as on the levels of antigen-specific IgGs in 
seropositive individuals. We observed a low impact of age and sex with total 
immunoglobulin levels (Figure 3A and Table S5), and of sex with specific IgG levels (Mumps 
and VZV; Figure S5A and C). In contrast, age had a strong impact on specific IgG levels in 
seropositive individuals, affecting 10 out of the 15 examined serologies (Figure 3B, Figure 
S5B and Table S5). Correlations between age and IgG were mostly positive, i.e. older donors 
had more specific IgG than younger donors, as for example in the case of Rubella (Figure 3C, 
left panel). The notable exception was T. gondii, where we observed lower amounts of 
specific IgG in older individuals (b=-0.013(-0.019, -0.007), P=3.7x10-6, Figure 3C, right panel).  
 
Genome-wide association study of serostatus 
To test if human genetic factors influence the rate of seroconversion upon exposure, we 
performed genome-wide association studies. Specifically, we searched for associations 
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between 5.7 million common polymorphisms (MAF > 5%) and the 15 serostatus in the 1,000 
healthy donors. Based on our results regarding age and sex, we included both as covariates 
in all models. After correcting for the number of antigens tested, the threshold for genome-
wide significance was Pthreshold = 3.3 x 10-9, for which we did not observe any significant 
association. In particular, we did not replicate the previously reported associations with H. 
Pylori serostatus on chromosome 1 (rs368433, P = 0.67, OR = 0.93) and 4 (rs10004195, P = 
0.83, OD = 0.97) [29].  
 
We then focused on the HLA region and confirmed the previously published association of 
influenza A serostatus with specific amino acid variants of HLA class II molecules [11]. The 
strongest association in the MI cohort was found with residues at position 31 of the HLA-
DRβ1 subunit (omnibus P = 0.009, Table S6). Residues found at that position, isoleucine (P = 
0.2, OD (95% CI) = 0.8 (0.56, 1.13)) and phenylalanine (P = 0.2, OR (95% CI) = 0.81 (0.56, 
1.13)), are consistent in direction and in almost perfect linkage disequilibrium (LD) with the 
glutamic acid residue at position 96 in HLA-DRβ1 that was identified in the previous study 
(Table S7). As such, our result independently validates the previous observation. 
 
Genome-wide association study of total and antigen-specific antibody levels 
To test whether human genetic factors also influence the intensity of antigen-specific 
immune response, we performed genome-wide association studies of total IgG, IgM, IgA 
and IgE levels, as well as antigen-specific IgG levels. 
 
Using a significance threshold of Pthreshold < 1.3 x 10-8, we found no SNPs associated with 
total IgG, IgM, IgE and IgA levels. However, we observed nominal significance and the same 
direction of the effect for 3 out of 11 loci previously published for total IgA [12, 30, 31, 32, 
33], 1 out of 6 loci for total IgG [12, 30, 34] and 4 out of 11 loci for total IgM [12, 35] (Table 
S8). Finally, we also report a suggestive association (genome-wide significant, P < 5.0 x 10-8, 
but not significant when correcting for the number of immunoglobulin classes tested in the 
study) of a SNP rs11186609 on chromosome 10 with total IgA levels (P = 2.0 x 10-8, beta = -
0.07 for the C allele). The closest gene for this signal is SH2D4B. 
 
We next explored associations between human genetic variants and antigen-specific IgG 
levels in seropositive donors (Pthreshold < 3.3 x 10-9). We detected significant associations for 
anti-EBV (EBNA antigen) and anti-rubella IgGs. Associated variants were in both cases 
located in the HLA region on chromosome 6. For EBV, the top SNP was rs74951723 (P = 3 x 
10-14, beta = 0.29 for the A allele) (Figure 4A). For rubella, the top SNP was rs115118356 (P = 
7.7 x 10-10, beta = -0.11 for the G allele) (Figure 4B). rs115118356 is in LD with rs2064479, 
which has been previously reported as associated with titers of anti-rubella IgGs (r2 = 0.53 
and D' = 0.76) [36].  
 
To fine map the associations observed in the HLA region, we tested 4-digit HLA alleles and 
variable amino positions in HLA proteins. At the level of HLA alleles, HLA-DQB1*03:01 
showed the lowest P-value for association with EBV EBNA (P = 1.3 x 10-7), and HLA-
DPB1*03:01 was the top signal for rubella (P = 3.8 x 10-6). At the level of amino acid 
positions, position 58 of the HLA-DRb1 protein associated with anti-EBV (EBNA antigen) IgG 
levels (P = 2.5 x 10-11). This is consistent with results of previous studies linking genetic 
variations in HLA-DRβ1 with levels of anti-EBV EBNA-specific IgGs [4, 11, 37] (Table S9). In 
addition, position 8 of the HLA-DPb1 protein associated with anti-rubella IgG levels (P = 1.1 x 
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10-9, Table 1). Conditional analyses on these amino-acid positions did not reveal any 
additional independent signals.  
 
Table 1. Significant associations with EBV EBNA and Rubella antigens at the level of SNP, HLA 
allele and protein amino acid position  
  Phenotype 
  EBV EBNA IgG levels Rubella IgG levels  
SNP 
ID (Allele) rs74951723 (A) rs115118356 (G) 
P-value 3 x 10-14  7.68 x 10-10  
Beta (95% CI) 0.29 (0.21, 0.36)  -0.11 (-0.15, -0.08) 
Classical HLA 
allele 
Allele  HLA-DQB1*03:01  HLA-DPB1*03:01  
P-value 1.26 x 10-7 3.8 x 10-6 
Beta (95% CI) 0.17 (0.11, 0.23)  -0.12 (-0.18, -0.07) 
Amino acid Protein (position) HLA-DRβ1 (56) HLA-DPβ1 (8) Omnibus P-value 2.53 x 10-11 1.12 x 10-9 
 
KIR associations 
To test whether specific KIR genotypes, and their interaction with HLA molecules, are 
associated with humoral immune responses, we imputed KIR alleles from SNP genotypes 
using KIR*IMP. First, we searched for potential associations with serostatus or IgG levels for 
16 KIR alleles that had a MAF > 1%. After correction for multiple testing, we did not find any 
significant association (Pthreshold < 2.6 x 10-4). Second, we tested specific KIR-HLA 
combinations. We filtered out rare combinations by removing pairs that were observed less 
then 4 times in the cohort.  After correction for multiple testing (Pthreshold < 5.4 × 10-7), we 
observed significant associations between total IgA levels and the two following HLA-KIR 
combinations: HLA-B*14:02/ KIR3DL1 and HLA-C*08:02/ KIR2DS4 (P = 3.9 x 10-9 and P = 4.9 x 
10-9 respectively, Table 2).  
 
Table 2. Association testing between KIR-HLA interactions and serology phenotypes 
 
Phenotype KIR HLA Estimate Std. Error P-value 
IgA levels KIR3DL1 HLA-B*14:02 0.456 0.077 3.9x10-09 
IgA levels KIR2DS4 HLA-B*14:02 0.454 0.077 4.5x10-09 
IgA levels KIR3DL1 HLA-C*08:02 0.449 0.076 4.9x10-09 
IgA levels KIR2DS4 HLA-C*08:02 0.448 0.076 5.7x10-09 
 
Burden testing for rare variants 
Finally, to search for potential associations between the burden of low frequency variants 
and the serological phenotypes, we conducted a rare variant association study. This analysis 
only included variants annotated as missense or putative loss-of-function (nonsense, 
essential splice-site and frame-shift, N=84,748), which we collapsed by gene and tested 
together using the kernel-regression-based association test SKAT [28]. We restricted our 
analysis to genes that contained at least 5 variants. Two genes were identified as 
significantly associated with total IgA levels using this approach: ACADL (P = 3.4 x 10-11) and 
TMEM131 (P=7.8 x 10-11) (Table 3). By contrast, we did not observe any significant 
associations between rare variant burden and antigen-specific IgG levels or serostatus. 
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Table 3. Significant associations of rare variants collapsed per gene set with IgA levels. 
 
Phenotype Chromosome Gene P-value Q 
No of Rare 
Markers 
No of Common 
Markers 
IgA levels 2 ACADL 3.42x10
-11 18.09 5 2 
2 TMEM131 7.83x10-11 17.89 13 2 
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Discussion 
 
We performed genome-wide association studies for a number of serological phenotypes in a 
well-characterized age- and sex-stratified cohort, and included a unique examination of 
genetic variation at HLA and KIR loci, as well as KIR-HLA associations. As such, our study 
provides a broad resource for exploring the variability in humoral immune responses across 
different isotypes and different antigens in humans.  
 
Using a fine-mapping approach, we replicated the previously reported associations of 
variation in the HLA-DRb1 protein with influenza A serostatus and anti-EBV IgG titers [4, 11], 
implicating amino acid residues in strong LD with the ones previously reported (Hammer et 
al.). We also replicated an association between HLA class II variation and anti-Rubella IgG 
titers [36], and further fine-mapped it to position 8 of the HLA-DPb1 protein. Interestingly, 
position 8 of HLA-DPb1, as well as positions 58 and 31 of HLA-DRb1, are all part of the 
extracellular domain of the respective proteins. Our findings confirm these proteins as 
critical elements for the presentation of processed peptide to CD4+ T cells, and as such may 
reveal important clues in the fine regulation of class II antigen presentation. We also 
identified specific HLA/KIR combinations, namely HLA-B*14:02/KIR3DL1 and HLA-
C*08:02/KIR2DS4, which associate with higher levels of circulating IgA. Given the novelty of 
KIR imputation method and the lack of possibility of benchmarking its reliability in the MI 
cohort further replication of these results will be needed. Yet these findings support the 
concept that variations in the sequence of HLA Class II molecules, or specific KIRs/HLA class I 
interactions play a critical role in shaping humoral immune responses in humans. In 
particular, our findings confirm that small differences in the capacity of HLA class II 
molecules to bind specific viral peptides can have a measurable impact on downstream 
antibody production. As such, our study emphasizes the importance of considering HLA 
diversity in disease association studies where associations between IgG levels and 
autoimmune diseases are being explored.  
 
We identified nominal significance for some but not all of the previously reported 
associations with levels of total IgG, IgM and IgA, as well as a suggestive association of total 
IgA levels with an intergenic region on chromosome 10 - closest gene being SH2D4B. By 
collapsing the rare variants present in our dataset into gene sets and testing them for 
association with the immunoglobulin phenotypes, we identified two additional loci that 
participate to natural variation in IgA levels. These associations mapped to the genes ACADL 
and TMEM131. ACADL encodes an enzyme with long-chain acyl-CoA dehydrogenase activity, 
and polymorphisms have been associated with pulmonary surfactant dysfunction [38]. As 
the same gene is associated with levels of circulating IgA in our cohort, we speculate that 
ACADL could play a role in regulating the balance between mucosal and circulating IgA. 
Further studies will be needed to test this hypothesis, as well as the potential impact of our 
findings in other IgA-related diseases.  
 
We were not able to replicate previous associations of TLR1 and FCGR2A locus with 
serostatus for H. Pylori [29]. We believe this may be a result of notable differences in 
previous exposure among the different cohorts as illustrated by the different levels of 
seropositivity; 17% in the Milieu Interieur cohort, versus 56% in the previous ones, reducing 
the likelihood of replication due to decreased statistical power. 
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In addition to genetics findings, our study re-examined the impact of age and sex, as well as 
non-genetic variables, on humoral immune responses. Although this question has been 
previously addressed, our well-stratified cohort brings interesting additional insights. One 
interesting finding is the high rate of seroconversion for CMV, HSV-1, and T. Gondii during 
adulthood. In our cohort, the likelihood of being seropositive for one of these infections is 
comparable at age 20 and 40. Given the high prevalence of these microbes in the 
environment, this raises questions about the factors that prevent some individuals from 
becoming seropositive upon late life exposure.  Second, both age and sex have a strong 
correlation with serostatus, i.e. older and female donors were more likely to be 
seropositive. Although increased seropositivity with age probably reflects continuous 
exposure, the sex effect is intriguing. Indeed, our study considered humoral responses to 
microbial agents that differ significantly in terms of physiopathology and that do not 
necessarily have a childhood reservoir. Also, our analysis show that associations persist after 
removal of potential confounding factors such as marital status, and/or number of kids. As 
such, we believe that our results may highlight a general impact of sex on humoral immune 
response variability, i.e. a tendency for women to be more likely to seroconvert after 
exposure, as compared to men of same age. This result is in line with observations from 
vaccination studies, where women responded to lower vaccine doses [39]. Finally, we 
observed an age-related increase in antigen-specific IgG levels in seropositive individuals for 
most serologies, with the notable exception of toxoplasmosis. This may indicate that aging 
plays a general role in IgG production. An alternative explanation that requires further study 
is that this could be the consequence of reactivation or recurrent exposure. 
 
In sum, our study provides evidence that age, sex and host genetics contribute to natural 
variation in humoral responses in humans. The identified associations have the potential to 
help improve vaccination strategies, and/or dissect pathogenic mechanisms implicated in 
human diseases related to immunoglobulin production such as autoimmunity. 
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Figure legends 
 
Fig.1 Overview of the study. 
Serum samples from the 1,000 age- and sex-stratified healthy individuals of the Milieu 
Intérieur cohort were used for measuring total antibody levels (IgA, IgM, IgG and IgE), as 
well as for qualitative (serostatus) and quantitative (IgG levels) assessment of IgG responses 
against cytomegalovirus, Epstein-Barr virus (anti-EBNA, anti-VCA, anti-EA), herpes simplex 
virus 1 & 2, varicella zoster virus, Helicobacter pylori, Toxoplasma gondii, influenza A virus, 
measles, mumps, rubella, and hepatitis B virus (anti-HBs and anti-HBc), using clinical-grade 
serological assays. 
 
Fig.2 Age and sex impact on serostatus. 
(A) Odd ratios of significant associations (adjusted P-values (adj. P<0.05) between age (<45 = 
reference, vs. >45 yrs.old) and serostatus as determined based on clinical-grade serologies 
in the 1,000 healthy individuals from the Milieu Intérieur cohort. Odd ratios were estimated 
in a generalized linear mixed model, with serostatus as response variable, and age and sex 
as treatment variables. Dots represent the mean of the odd ratios. Lines represent the 95% 
confidence intervals. (B) Odds of being seropositive towards EBV EBNA (Profile 1; upper 
left), Toxoplasma gondii (Profile 2; upper right), Helicobacter Pylori (Profile 3; bottom left), 
and HBs antigen of HBV (Profile 4; bottom right), as a function of age in men (blue) and 
women (red) in the 1,000 healthy donors. Indicated P-values were obtained using a logistic 
regression with Wald test, with serostatus binary variables (seropositive, versus 
seronegative) as the response, and age and sex as treatments. (C) Odd ratios of significant 
associations (adjusted P-values (adj. P<0.05) between sex (Men=reference, vs. Women) and 
serostatus. Odd ratios were estimated in a generalized linear mixed model, with serostatus 
as response variable, and age and sex as treatment variables. Dots represent the mean of 
the odd ratios. Lines represent the 95% confidence intervals. 
 
Fig.3 Age and sex impact on total and antigen-specific antibody levels. 
(A) Relationships between Log10-transformed IgG (upper left), IgA (upper right), IgM 
(bottom left) and IgE (bottom right) levels and age. Regression lines were fitted using linear 
regression, with Log10-transformed total antibody levels as response variable, and age and 
sex as treatment variables. Indicated adj. P were obtained using the mixed model, and 
corrected for multiple testing using the FDR method. (B) Effect sizes of significant 
associations (adjusted P-values (adj. P<0.05) between age and Log10-transformed antigen-
specific IgG levels in the 1,000 healthy individuals from the Milieu Intérieur cohort. Effect 
sizes were estimated in a linear mixed model, with Log10-transformed antigen-specific IgG 
levels as response variables, and age and sex as treatment variables. Dots represent the 
mean of the beta. Lines represent the 95% confidence intervals. (C) Relationships between 
Log10-transformed anti-rubella IgGs (left), and Log10-transformed anti-toxoplasma gondii 
IgGs (right) and age. Regression lines were fitted using linear regression described in (B). 
Indicated adj. P were obtained using the mixed model, and corrected for multiple testing 
using the FDR method. 
 
Fig.4 Association between host genetic variants and serological phenotypes 
Manhattan plots of association results for (A) EBV anti-EBNA IgG, (B) Rubella IgG levels. The 
dashed horizontal line denotes genome-wide significance (P = 3.3 x 10-9).  
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Fig.S1 Distribution of serological variables, and clinical threshold used for determination 
of serostatus. 
(A) Distribution and probability density curve of Log10-transformed IgG, IgM, IgA, IgE levels 
in the 1,000 study participants. (B) Distribution of Log10-transformed antigen-specific IgG 
levels. The vertical lines indicate the clinical threshold determined by manufacturer, and 
used for determining the serostatus of the donors for each serology. 
 
Fig.S2 Seroprevalence data in the 1,000 healthy donors. 
(A) Percentage of seropositive donors for each indicated serology in the MI study (for HBV 
serology, percentages of anti-HBs IgGs are indicated). (B) Distribution of the number of 
positive serologies in the 1,000 healthy donors regarding the 8 persistent or recurrent 
infections tested in our study (i.e. CMV, Influenza, HSV1, HSV2, TP, EBV_EBNA, VZV, HP). 
 
Fig.S3 Impact of non-genetic factors, age, and sex on serostatus. 
(A) Adjusted P-values (FDR) of the large-sample chi-square likelihood ratio tests of effect of 
non-genetic variables on serostatus, obtained from mixed models. (B-C) Adjusted P-values 
(adj. P) of the tests of effect of age (<45 = reference, vs. >45 years old) (B) and sex (Men = 
reference, vs. Women) (C) on serostatus, obtained using a generalized linear mixed model, 
with serostatus as response variables, and age and sex as treatment variables. Odd ratios 
were color-coded. Vertical black line indicates the -log10 of the chosen threshold for 
statistical significance (-log10(0.05) = 1.30103). 
 
Fig.S4 Evolution of serostatus with age and sex. 
(A-O) Odds of being seropositive for each of the 15 antigens considered in our study, as a 
function of age in men (blue) and women (red). Indicated P-values were obtained using a 
logistic regression with Wald test, with serostatus binary variables (seropositive, versus 
seronegative) as the response, and age and sex as covariates. 
 
Fig.S5 Impact of age and sex on antigen-specific IgG levels. 
(A) Effect sizes of significant associations (adjusted P-values (adj. P<0.05) between sex and 
Log10-transformed antigen-specific IgG levels in the 1,000 healthy individuals from the 
Milieu Intérieur cohort. Effect sizes were estimated in a linear mixed model described in 
(Figure 3B). Dots represent the mean of the beta. Lines represent the 95% confidence 
intervals. (B-C) Adjusted P-values (adj. P) of the tests of effect of age (B) and sex (C) on 
Log10-transformed antigen-specific IgG levels, obtained using a linear mixed model, with 
Log10-transformed antigen-specific IgG levels as response variables, and age and sex as 
treatment variables. Normalized effect sizes were color-coded. The vertical black line 
indicates the -log10 of the threshold for statistical significance (-log10(0.05) = 1.30103). 
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